Table 5.

Subanalyses of the primary endpoint

Sub‐endpoint analyzed	Group	Number reaching components of the primary endpoint in the final analysis		Number censored	Median time to reaching sub‐endpoint (95% confidence interval) (days)	Hazard ratio of the pimobendan group compared to the placebo group (95% confidence interval)	P‐value for comparison (log‐rank)
Verified congestive heart failure	Pimobendan	59/178 (33.1%)		119/178 (66.9%)	1337 (1126‐NA)	0.58 (0.42–0.82)	.0018
	Placebo	76/176 (43.2%)		100/176 (56.8%)	846 (730–1138)
Cardiac death or euthanasia	Pimobendan	15/178 (8.4%)	SCD = 12/178 (6.7%)	163/178 (91.6%)	Median not reached in 1570 days (NA)	0.96 (0.45–2.1)	.92
			CE = 3/178 (1.7%)
	Placebo	12/176 (6.8%)	SCD = 5/176 (2.8%)	164/176 (93.2%)	Median not reached in 1570 days (1282‐NA)
			CE = 7/176 (4.0%)

CE, cardiac euthanasia; NA, Not able to calculate; SCD, spontaneous cardiac death.